How a protein shake could fight the side effects of Ozempic and Wegovy | A protein shake has been developed to combat the severe muscle loss linked to hugely popular slimming drugs
Future research should prioritise wellpowered clinical trials, individual patient data metaanalyses, and longerterm followup studies, particularly in pregnancy, to better define the populations most likely to benefit from metformin use across the PCOS spectrum
In animal studies, BPC-157 has been reported to upregulate vascular endothelial growth factor (VEGF) and its receptor VEGFR2, which supports the formation of capillaries needed to deliver oxygen and nutrients to healing tissue
Anti-Doping Agency (USADA). It falls under Category S2: Peptide Hormones, Growth Factors, Related Substances, and Mimetics on the WADA Prohibited List, often specified as a "Growth Hormone Releasing Hormone (GHRH) and its analogues" or a "Growth Hormone Secretagogue (GHS)". The ban is due to its potential to unfairly enhance athletic performance by increasing muscle mass, strength, reducing fat, and improving recovery. The prohibition applies regardless of its mechanism of stimulating endogenous GH, as the outcome of artificially elevated GH/IGF-1 is the concern
Wegovy FDA-approved specifically for weight loss , containing a higher dosage of Semaglutide than Ozempic
